These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 14688491)

  • 21. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renin- and non-renin-mediated antihypertensive actions of converting enzyme inhibitors.
    Zusman RM
    Kidney Int; 1984 Jun; 25(6):969-83. PubMed ID: 6088887
    [No Abstract]   [Full Text] [Related]  

  • 23. Obesity hypertension: the rationale for renin-angiotensin system blockade.
    Chan NN; Tong PC; Kong AP; Chan JC
    Hong Kong Med J; 2005 Jun; 11(3):217-20. PubMed ID: 15951590
    [No Abstract]   [Full Text] [Related]  

  • 24. Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease.
    Andersen NH; Mogensen CE
    Curr Hypertens Rep; 2004 Oct; 6(5):369-76. PubMed ID: 15341690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aliskiren in the management of hypertension.
    Barrios V; Escobar C
    Am J Cardiovasc Drugs; 2010; 10(6):349-58. PubMed ID: 21090828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is the plasma aldosterone-to-renin ratio associated with blood pressure response to treatment in general practice?
    Käyser SC; Schalk BWM; de Grauw WJC; Schermer TR; Akkermans RP; Lenders JWM; Deinum J; Biermans MCJ
    Fam Pract; 2019 Mar; 36(2):154-161. PubMed ID: 29788258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertension management: differing points of view. Should we routinely measure renin levels to diagnose and treat patients with hypertension? The argument for.
    August P
    J Clin Hypertens (Greenwich); 2005 Jan; 7(1):33-5; quiz 38-9. PubMed ID: 15655385
    [No Abstract]   [Full Text] [Related]  

  • 29. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans.
    Danser AH; Derkx FH; Schalekamp MA; Hense HW; Riegger GA; Schunkert H
    J Hypertens; 1998 Jun; 16(6):853-62. PubMed ID: 9663926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct renin inhibitors in hypertension - approaching the moment of truth.
    Hedner T; Narkiewicz K; Oparil S; Kjeldsen SE
    Blood Press; 2012 Oct; 21(5):267-8. PubMed ID: 23013445
    [No Abstract]   [Full Text] [Related]  

  • 31. [Erythropoietin-induced hypertension].
    Ioka T; Kusano E
    Nihon Rinsho; 2006 Sep; Suppl 3():513-6. PubMed ID: 17022600
    [No Abstract]   [Full Text] [Related]  

  • 32. The renin-angiotensin system antagonism in the treatment of hypertension.
    Bisognano JD; Cody RJ
    Curr Hypertens Rep; 1999 Aug; 1(4):275-7. PubMed ID: 10981078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma renin activity and aldosterone concentrations in hypertensive cats with and without azotemia and in response to treatment with amlodipine besylate.
    Jepson RE; Syme HM; Elliott J
    J Vet Intern Med; 2014; 28(1):144-53. PubMed ID: 24428319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition.
    Moore N; Dicker P; O'Brien JK; Stojanovic M; Conroy RM; Treumann A; O'Brien ET; Fitzgerald D; Shields D; Stanton AV
    Hypertension; 2007 Aug; 50(2):340-7. PubMed ID: 17562974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of antihypertensive treatment based on plasma renin activity: An open label observational study.
    Leotta G; Rabbia F; Testa E; Totaro S; Abram S; Milan A; Mulatero P; Veglio F
    Blood Press; 2010 Aug; 19(4):218-24. PubMed ID: 20367559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension.
    Giles TD; Bakris G; Oparil S; Weber MA; Li H; Mallick M; Bharucha DB; Chen C; Ferguson WG;
    J Am Soc Hypertens; 2015 Nov; 9(11):845-54. PubMed ID: 26362831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.
    Sezai A; Soma M; Hata M; Yoshitake I; Unosawa S; Wakui S; Shiono M
    Ann Thorac Cardiovasc Surg; 2011; 17(5):487-93. PubMed ID: 21881353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Historical perspective of renin-angiotensin system blocking in the treatment of arterial hypertension].
    Coca A; Redón J
    Med Clin (Barc); 1996 Mar; 106(12):457-9. PubMed ID: 8656731
    [No Abstract]   [Full Text] [Related]  

  • 40. Diabetic hypertension.
    Khan KA; Govindarajan G; Whaley-Connell A; Sowers JR
    Heart Fail Clin; 2006 Jan; 2(1):25-36. PubMed ID: 17386874
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.